Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266

1.

Current status of co-occurring mood and substance use disorders: a new therapeutic target.

Pettinati HM, O'Brien CP, Dundon WD.

Am J Psychiatry. 2013 Jan;170(1):23-30. doi: 10.1176/appi.ajp.2012.12010112. Review.

2.

[Co-occuring mood and substance use disorders].

Adida M, Kaladjian A, Fakra E, Belzeaux R, Azorin JM.

Encephale. 2014 Dec;40 Suppl 3:S8-S13. doi: 10.1016/S0013-7006(14)70124-1. Review. French.

PMID:
25550243
3.

Naltrexone in patients with bipolar disorder and alcohol dependence.

Brown ES, Beard L, Dobbs L, Rush AJ.

Depress Anxiety. 2006;23(8):492-5.

PMID:
16841344
4.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.

Beaulieu S, Saury S, Sareen J, Tremblay J, Sch├╝tz CG, McIntyre RS, Schaffer A; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.

Ann Clin Psychiatry. 2012 Feb;24(1):38-55. Review.

PMID:
22303521
5.

[Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Wobrock T, D'Amelio R, Falkai P.

Nervenarzt. 2008 Jan;79(1):17-8, 20-2, 24-6 passim. Review. German.

PMID:
17619840
6.

A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence.

Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, Findling RL, Calabrese JR.

J Clin Psychiatry. 2009 Jan;70(1):113-21. Epub 2008 Dec 30.

7.

Major depression and comorbid substance use disorders.

Davis L, Uezato A, Newell JM, Frazier E.

Curr Opin Psychiatry. 2008 Jan;21(1):14-8. doi: 10.1097/YCO.0b013e3282f32408. Review.

PMID:
18281835
8.

Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence.

Horsfall J, Cleary M, Hunt GE, Walter G.

Harv Rev Psychiatry. 2009;17(1):24-34. doi: 10.1080/10673220902724599. Review.

PMID:
19205964
9.

Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort.

Davis LL, Rush JA, Wisniewski SR, Rice K, Cassano P, Jewell ME, Biggs MM, Shores-Wilson K, Balasubramani GK, Husain MM, Quitkin FM, McGrath PJ.

Compr Psychiatry. 2005 Mar-Apr;46(2):81-9.

PMID:
15723023
10.

Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.

Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.

J Clin Psychiatry. 2011 Aug;72(8):1144-51. doi: 10.4088/JCP.10m06217. Epub 2011 Apr 19.

PMID:
21536001
11.

Naltrexone and disulfiram in patients with alcohol dependence and current depression.

Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J, Rounsaville B; VA VISN I MIRECC Study Group.

J Clin Psychopharmacol. 2007 Apr;27(2):160-5.

PMID:
17414239
12.

Mood disorders in the elderly.

Gebretsadik M, Jayaprabhu S, Grossberg GT.

Med Clin North Am. 2006 Sep;90(5):789-805. Review.

PMID:
16962842
13.

Management of comorbid bipolar disorder and substance abuse.

Vornik LA, Brown ES.

J Clin Psychiatry. 2006;67 Suppl 7:24-30. Review.

14.

Substance use and the treatment of resistant depression in adolescents.

Goldstein BI, Shamseddeen W, Spirito A, Emslie G, Clarke G, Wagner KD, Asarnow JR, Vitiello B, Ryan N, Birmaher B, Mayes T, Onorato M, Zelazny J, Brent DA.

J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1182-92. doi: 10.1097/CHI.0b013e3181bef6e8.

15.

A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.

Adamson SJ, Sellman JD, Foulds JA, Frampton CM, Deering D, Dunn A, Berks J, Nixon L, Cape G.

J Clin Psychopharmacol. 2015 Apr;35(2):143-9. doi: 10.1097/JCP.0000000000000287.

PMID:
25679122
16.

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.

Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP.

Am J Psychiatry. 2010 Jun;167(6):668-75. doi: 10.1176/appi.ajp.2009.08060852. Epub 2010 Mar 15.

17.

Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.

Brunette MF, Noordsy DL, Xie H, Drake RE.

Psychiatr Serv. 2003 Oct;54(10):1395-401.

PMID:
14557527
18.

The impact of co-occurring mood and anxiety disorders among substance-abusing youth.

Lubman DI, Allen NB, Rogers N, Cementon E, Bonomo Y.

J Affect Disord. 2007 Nov;103(1-3):105-12. Epub 2007 Feb 8.

PMID:
17291589
19.

Outcomes of an integrated cognitive behaviour therapy (CBT) treatment program for co-occurring depression and substance misuse in young people.

Hides L, Carroll S, Catania L, Cotton SM, Baker A, Scaffidi A, Lubman DI.

J Affect Disord. 2010 Feb;121(1-2):169-74. doi: 10.1016/j.jad.2009.06.002. Epub 2009 Jul 14.

PMID:
19604584
20.

Treatment of patients comorbid for addiction and other psychiatric disorders.

Brady KT, Verduin ML, Tolliver BK.

Curr Psychiatry Rep. 2007 Oct;9(5):374-80. Review.

PMID:
17915076

Supplemental Content

Support Center